Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2020
STOCKHOLM, 20 November 2020 – Promore Pharma AB (publ) publishes its interim report for the third quarter 2020 on 24 November 2020.
The next day, 25 November, the company will host a webcast telephone conference at 10.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and the recently released HEAL study will be provided. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
The conference call will be recorded and made available on the company´s website after the call, and on
Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Promore Pharma’s Certified Adviser is Redeye AB.
Phone: [+46] 8 121 576 90
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company’s aim is to develop first-in-category pharmaceuticals for indications where very few efficacious prescription pharmaceuticals are available, thus, addressing high unmet medical needs. Promore Pharma’s two projects are in late stage clinical development phase and have a very strong safety profile since they are based on innate substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical adhesions and scars, is being prepared for clinical phase III-studies in patients undergoing tendon repair surgery in the hand. Ropocamptide (LL-37) has recently finalized a clinical phase IIb study in patients with venous leg ulcers (VLU). The product candidates can also be deployed for other indications, such as preventing dermal scarring, adhesions after other surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market
Arcoma launches new X-ray system OMNERA 500A on the US market
The OMNERA 500A offers outstanding performance and intelligent automation with features that puts efficiency and patient safety first. The system has a new design and a new modern user interface with smart functions that simplify workflow and are designed to facilitate disinfection. The OMNERA 500A...
Arcoma lanserar nya röntgensystemet OMNERA 500A på amerikanska marknaden
OMNERA 500A erbjuder enastående prestanda och intelligent automatisering med funktioner som sätter effektivitet och patientsäkerhet främst. Systemet har ny design och ett nytt modernt användargränsnitt med smarta funktioner som förenklar arbetsflödet och är utformat för att underlätta desinficering....
Brighter’s Nomination Committee for the Annual Shareholders’ Meeting 2021
Brighter’s Nomination Committee for the Annual Shareholders’ Meeting 2021 has been appointed based on the ownership structure as of 30 September 2020 in line with the nomination committee instruction that was adopted at the 2020 Annual General Meeting. The Nomination Committee shall consist of Brigh...
Valberedning för Brighter AB (publ) inför årsstämman 2021
Valberedningen för Brighter AB inför årsstämman 2021 har utsetts baserat på ägarförhållandena den 30 september 2020 i enlighet med valberedningens instruktion som antogs vid årsstämman 2020. Valberedningen ska utgöras av Brighters styrelseordförande samt representanter för de röstmässigt tre största...